MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today

Locations
Careers
Contact Us
Our Doctors
- Español
- عربى
- 中文
- Türkçe

Clear

close

Search MD Anderson

MyChart

Donate Today

Locations
Careers
Contact Us
- Español
- عربى
- 中文
- Türkçe

Request an Appointment
New Patients
Current Patients
Referring Physicians

Patients & Family
Prevention & Screening
Donors & Volunteers
For Physicians
Research
Education & Training

Diagnosis & Treatment

Clinical Trials

Clinical Trials Detail

Top

Study #2004-0223

Phase II Study of 2-Chlorodeoxyadenosine (2CDA) Followed by Rituximab in Hairy Cell Leukemia

MD Anderson Study Status

Enrolling

Treatment Agent

Cladribine, Rituximab

Description

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cladribine together with rituximab may kill more cancer cells.